Eight Questions for a Missed Diagnosis: Shortening the Hypomania Checklist
- In 760 clinically diagnosed patients (171 with bipolar disorder, 589 with major depression), three abbreviated Lebanese Arabic versions of the Hypomania Checklist (HCL-20, HCL-16, HCL-8) were tested against the full 32-item original.
- All shortened versions held strong internal reliability (alpha 0.78 to 0.90) and good discrimination between bipolar disorder and unipolar depression (AUC 0.852 to 0.884), with no meaningful loss versus the full scale.
- The HCL-16 emerged as the optimal trade-off, separating bipolar from depressive presentations as well as the longer forms while cutting administration time roughly in half.
- Sensitivity was consistently higher for bipolar-II versus depression than for bipolar-I versus depression, meaning the shortened checklists are best at catching the softer, more easily missed end of the bipolar spectrum.
Bipolar disorder is one of the most frequently missed diagnoses in clinical practice. Patients almost always present during a depressive episode, and the hypomanic periods that would reveal the bipolar nature of their illness are rarely the reason they seek help and are often forgotten or reframed as "just feeling good." The result is a well-documented diagnostic lag: years pass, antidepressant monotherapy is prescribed without a mood stabiliser, and the underlying bipolarity surfaces only after a destabilising episode. The Hypomania Checklist (HCL-32), a patient-completed retrospective screen, was designed to close exactly this gap by probing whether a person has ever experienced a sustained "high" state.
The problem with the HCL-32 is in its name: thirty-two items is a lot to ask of a depressed patient in a busy consultation, and length is one of the most reliable predictors of an instrument being skipped. This study set out to find how much of the checklist can be cut before its screening value degrades. Working with 760 patients in Lebanon, all carrying a clinical diagnosis of either bipolar disorder or major depression, the authors built and tested three progressively shorter Arabic versions: 20 items, 16 items, and a notably lean 8-item form.
The reassuring result is that brevity was nearly free. Reliability stayed high across all three short forms, and the area under the curve, the standard summary of a screener's ability to separate two groups, barely moved from the full version. The 16-item form was the sweet spot: it matched the longer scales statistically while halving the burden. Even the 8-item version retained usable discrimination, which is striking for a screen that asks only a handful of questions.
The more clinically interesting finding sits in the asymmetry of sensitivity. The short forms detected bipolar-II disorder against depression more reliably than bipolar-I against depression. At first this seems counter-intuitive, since bipolar-I, with full manic episodes, is the more severe condition. But bipolar-I is also more obvious; its episodes tend to force themselves into the clinical record. Bipolar-II, defined by hypomania, is precisely the population that slips through. A screen that performs best where diagnosis is hardest is doing the work that matters most.
For a practitioner, the takeaway is not that the HCL-32 was wrong, but that the friction of length was never worth its marginal accuracy. A 16-item or even 8-item checklist, handed to every depressed patient before antidepressant monotherapy is started, is a low-cost guard against one of the field's most consequential diagnostic errors.
Why Shorter Screeners Win in Practice
A measure's psychometric ceiling is irrelevant if clinicians do not use it. Screening instruments compete for the same scarce minutes as history-taking, risk assessment, and rapport. Every additional item lowers the probability that the tool is administered at all, especially with patients whose concentration and motivation are already eroded by depression. A validated short form is therefore not a compromised version of a better instrument; in real workflows it is frequently the better instrument, because it is the one that actually gets completed.
A Note on the Validation Sample
The sample composition deserves attention. With 589 depression cases against 171 bipolar cases, and only 29 bipolar-I patients, the dataset mirrors a realistic referral mix where depression dominates. That makes the bipolar-II findings credible, but the small bipolar-I subgroup means the lower sensitivity there should be read as a hypothesis to confirm rather than a settled limitation of the short forms.
A screen that performs best exactly where diagnosis is hardest is doing the clinical work that matters most.
The validation relied on retrospective data collection, which introduces recall bias into a checklist already built on patients remembering past mood states. The bipolar-I subgroup was very small (29 patients), so the weaker sensitivity for bipolar-I versus depression rests on thin numbers. Results come from a single Lebanese Arabic-speaking clinical population and require replication before the shortened cut points are applied to other languages or to community rather than clinical samples.